Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Phase II Pazopanib Study in Advanced Dermatofibrosarcomas
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 23
- Registration Number
- NCT01059656
- Locations
- 🇫🇷
Hôpital Saint-Louis - Service de Dermatologie (Pole POPS), Paris, France
A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT01051700
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Illinois CancerCare, P.C.
- Target Recruit Count
- 32
- Registration Number
- NCT01049776
- Locations
- 🇺🇸
Illinois CancerCare, P.C., Princeton, Illinois, United States
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Carcinoma
- Interventions
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01035658
- Locations
- 🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 41
- Registration Number
- NCT01031875
- Locations
- 🇮🇹
Fondazione Istituto Nazionale dei Tumori, Milan, Italy
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 202
- Registration Number
- NCT01027598
- Locations
- 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- Conditions
- Breast CancerLung CancerColon CancerPancreatic CancerHead and Neck CancerKidney CancerSarcomaHepatocellular Cancer
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 31
- Registration Number
- NCT01012362
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00992121
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2013-11-18
- Lead Sponsor
- Illinois CancerCare, P.C.
- Target Recruit Count
- 11
- Registration Number
- NCT00945477
- Locations
- 🇺🇸
Illinois CancerCare, Pekin, Illinois, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
- Conditions
- Childhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorMetastatic Childhood Soft Tissue SarcomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal Tumor
- Interventions
- Other: pharmacological study
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00929903
- Locations
- 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.